tetano
Editor, Senior Moderator
Intern Med
. 2022 May 31.
doi: 10.2169/internalmedicine.9136-21. Online ahead of print.
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma
Yayoi Ueda[SUP] 1 [/SUP], Shoji Asakura[SUP] 1 [/SUP], Sae Wada[SUP] 2 [/SUP], Takashi Saito[SUP] 3 [/SUP], Tomofumi Yano[SUP] 1 [/SUP]
Affiliations
Abstract
A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19). One month after the symptoms transiently improved, the patient experienced exacerbated COVID-19 symptoms. The patient recovered from COVID-19 with remdesivir and dexamethasone and was discharged 77 days after the disease onset. The patient completed a primary series of SARS-CoV-2 vaccinations on day 176, but the anti-spike protein IgG was not detected later. A careful observation to detect any subsequent relapse of COVID-19 symptoms is necessary in immunocompromised patients. Chemotherapy should be based on the disease status and type of lymphoma.
Keywords: follicular lymphoma; immunocompromised patient; obinutuzumab and bendamustine; prolonged COVID-19.
. 2022 May 31.
doi: 10.2169/internalmedicine.9136-21. Online ahead of print.
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma
Yayoi Ueda[SUP] 1 [/SUP], Shoji Asakura[SUP] 1 [/SUP], Sae Wada[SUP] 2 [/SUP], Takashi Saito[SUP] 3 [/SUP], Tomofumi Yano[SUP] 1 [/SUP]
Affiliations
- PMID: 35650124
- DOI: 10.2169/internalmedicine.9136-21
Abstract
A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19). One month after the symptoms transiently improved, the patient experienced exacerbated COVID-19 symptoms. The patient recovered from COVID-19 with remdesivir and dexamethasone and was discharged 77 days after the disease onset. The patient completed a primary series of SARS-CoV-2 vaccinations on day 176, but the anti-spike protein IgG was not detected later. A careful observation to detect any subsequent relapse of COVID-19 symptoms is necessary in immunocompromised patients. Chemotherapy should be based on the disease status and type of lymphoma.
Keywords: follicular lymphoma; immunocompromised patient; obinutuzumab and bendamustine; prolonged COVID-19.